Brief: Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005

Alumis

19/12/2024 13:23

Dec 19 (Reuters) - Alumis Inc  ALMS.O :
    * ALUMIS ANNOUNCES POSITIVE PHASE 1 DATA FOR CNS PENETRANT
TYK2
INHIBITOR, A-005
    * A-005 WAS WELL TOLERATED AND DEMONSTRATED ABILITY TO CROSS
BLOOD-BRAIN BARRIER
    * DATA SUPPORT ADVANCEMENT TO PHASE 2 CLINICAL TRIAL IN
MULTIPLE
SCLEROSIS, ANTICIPATED IN 2H 2025
    * MAXIMAL TYK2 INHIBITION ACHIEVED WITH FAVORABLE
PHARMACOKINETIC
PROFILE IN CNS AND PERIPHERY

Source text:  ID:nGNX8y7dPY 
Further company coverage:  ALMS.O 

 ((Reuters.Briefs@thomsonreuters.com;))